Exozymes (EXOZ) Total Current Liabilities (2023 - 2026)
Exozymes (EXOZ) posted quarterly Total Current Liabilities of $1.6 million for Q4 2025, up 17.53% year-over-year from $1.3 million in Q4 2024, and up 26.53% quarter-over-quarter from $1.2 million in Q3 2025.
Exozymes (EXOZ) Total Current Liabilities (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Total Current Liabilities for 3 consecutive years, with $1.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 17.53% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (up 17.53% YoY), while the FY2025 annual figure was $1.6 million, up 17.53% from the prior year.
- Total Current Liabilities advanced to $1.6 million in Q4 2025 per EXOZ's latest filing, from $1.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.8 million in Q3 2024 and bottomed at $1.2 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $2.1 million across 3 years, with a median of $1.4 million in 2025.
- On a YoY basis, Total Current Liabilities climbed as much as 17.53% in 2025 and fell as far as 78.66% in 2025.
- Exozymes' Total Current Liabilities stood at $2.4 million in 2023, then plunged by 44.8% to $1.3 million in 2024, then gained by 17.53% to $1.6 million in 2025.
- Business Quant data shows EXOZ's Total Current Liabilities at $1.6 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Exozymes | 61.53 Mn | 61.53 Mn | - | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Dec 31, 2023 | 2.42 Mn |